Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTOP: Neoadjuvant Toripalimab, Docetaxel, and Carboplatin in Localized TNBC
NCT06618014Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Jan 2022; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06618014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618014.